Acalabrutinib for CLL in routine care
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows people with CLL who are starting acalabrutinib (a targeted pill) for the first time, either as their first treatment or after previous therapies. The goal is to see how well it works in everyday medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of CLL.
- You must have just started or be about to start acalabrutinib alone (no other CLL drugs like obinutuzumab or venetoclax within 30 days of starting).
- You may be receiving treatment for CLL for the first time, or have relapsed or not responded to previous treatments.
- You must not have taken any other BTK inhibitor (a type of targeted drug) before.
- If you are female, you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how acalabrutinib, a targeted therapy for chronic lymphocytic leukemia (CLL), works in real-life settings in Spain. It aims to see how well it helps people who are starting treatment for the first time or switching due to side effects.
This Phase 2 trial studies whether acalabrutinib, and optionally adding obinutuzumab, can control early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see how well these treatments work and how safe they are in people who have not had prior treatment.
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
This study looks at quality of life in people with CLL who are taking acalabrutinib for the first time. It uses data already collected from a real-world database to see how patients feel and function.
This trial tests whether adding acalabrutinib to obinutuzumab plus venetoclax works better than the standard combo (obinutuzumab plus venetoclax) for people with untreated, high-risk CLL. It’s designed to see if the stronger mix can improve control of the leukemia with an acceptable safety profile.
This trial tests whether taking venetoclax on an intermittent schedule (not every day) works as well as taking it continuously when combined with acalabrutinib for people with untreated CLL or SLL. It aims to find a treatment approach that might be just as effective but with fewer side effects.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.